The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair.

MLA

Placheta, Eva, et al. “The ErbB2 Inhibitor Herceptin (Trastuzumab) Promotes Axonal Outgrowth Four Weeks after Acute Nerve Transection and Repair.” Neuroscience Letters, vol. 582, Oct. 2014, pp. 81–86. EBSCOhost, https://doi.org/10.1016/j.neulet.2014.09.006.

APA

Placheta, E., Hendry, J. M., Wood, M. D., Lafontaine, C. W., Liu, E. H., Cecilia Alvarez Veronesi, M., Frey, M., Gordon, T., & Borschel, G. H. (2014). The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair. Neuroscience Letters, 582, 81–86. https://doi.org/10.1016/j.neulet.2014.09.006

Chicago

Placheta, Eva, J Michael Hendry, Matthew D Wood, Christine W Lafontaine, Edward H Liu, M Cecilia Alvarez Veronesi, Manfred Frey, Tessa Gordon, and Gregory H Borschel. 2014. “The ErbB2 Inhibitor Herceptin (Trastuzumab) Promotes Axonal Outgrowth Four Weeks after Acute Nerve Transection and Repair.” Neuroscience Letters 582 (October): 81–86. doi:10.1016/j.neulet.2014.09.006.